United States Patent 5,457,895: Claim Scope, Expiration, and Fast-Dissolving Dosage-Form Patent Landscape

U.S. Patent No. 5,457,895 covers a manufacturing technique that transfers a tactile identifying mark from an embossed blister pocket to the surface of a fast-dissolving dosage form. The patent is directed to dosage-form manufacture and packaging geometry, not to a particular active pharmaceutical ingredient.

The patent was granted on October 10, 1995. Because the application predates the applicable change to the U.S. patent-term system, its ordinary statutory term was generally 17 years from grant. On that basis, the patent expired on October 10, 2012, absent a patent-term extension, adjustment, or unusual terminal-disclaimer issue. It therefore does not create a current U.S. patent barrier to generic or branded products. [1][2]

What does U.S. Patent 5,457,895 protect?

The patent protects a blister-based process for producing a fast-dissolving dosage form with a three-dimensional tactile identification mark.

The core sequence is:

Form a blister pocket.
Emboss an identifying mark into a generally continuous blister-pocket surface.
Introduce a liquid or other dosage-form material into the pocket.
Form the dosage directly in the pocket.
Transfer the embossed geometry to the dosage surface.

The independent claim concept requires both the embossed blister and the resulting embossed dosage form. A process that merely prints, laser-marks, debosses, or post-processes a tablet after removal from the blister would not fall within the literal wording of claim 1 unless it also satisfies the blister-formation and in-pocket formation limitations.

The commercial objective is product identification without relying solely on visual printing. The mark may identify dosage strength, manufacturer, or another product attribute.

What technical problem does the patent address?

Fast-dissolving dosage forms are often fragile, porous, and difficult to print or emboss after manufacture. The claimed process uses the blister cavity as a forming surface. The dosage form acquires:

An overall shape defined by the blister pocket.
A generally continuous surface corresponding to the blister surface.
A tactile elevated or depressed mark.
The mark’s position and geometry from the blister embossment.

The technique is particularly relevant to freeze-dried dosage forms formed in unit-dose blister packaging.

How do claims 1 through 8 define the manufacturing process?

Claim 1 is the principal process claim. It requires:

A blister pocket.
At least one generally continuous pocket surface.
An identifying embossment on that surface.
A fast-dissolving dosage form formed directly in the pocket.
A dosage surface corresponding to the pocket surface.
A tactile embossed mark corresponding to the blister embossment.

Claims 2 through 8 add narrower process limitations.

Claim	Added limitation	Commercial or technical significance
1	Dosage formed directly in an embossed blister pocket	Core transfer mechanism
2	Freeze-drying a liquid suspension in the pocket	Targets lyophilized or freeze-dried dosage forms
3	Elevated identifying mark	Raised tactile indicia
4	Depressed identifying mark	Recessed tactile indicia
5	Thermoformed blister pocket	Heated plastic forming process
6	Cold-formed blister pocket	Mechanical forming, often associated with metal laminate
7	Aluminum laminate blister	Supports foil-based packaging
8	Plastic laminate blister	Supports polymer blister structures

Claim 1 is broad as to the active ingredient, excipients, dosage strength, blister dimensions, and particular identifying symbol. It does not require a named drug, a specific polymer, a particular freeze-drying cycle, or a particular mark such as a letter, number, logo, or symbol.

The main limitation is functional and structural: the mark must be transferred from the embossed blister surface to the dosage form during formation.

What do claims 9 through 18 protect?

Claims 9 and 13 through 18 move from the manufacturing method to the resulting dosage form and package combination.

Claim 9: dosage form made by the claimed process

Claim 9 covers a fast-dissolving dosage form bearing an embossed identifying mark applied by the process of claim 1. Its scope depends heavily on how the product-by-process language is interpreted.

A product-by-process claim generally requires the claimed product characteristics, but the process language can create substantial construction and proof issues. A party seeking to enforce claim 9 would need to establish that the accused dosage form has the relevant embossed mark and falls within the claimed class of fast-dissolving dosage forms. The fact that a product was made by a different process may not avoid infringement if the resulting product is structurally indistinguishable and the claim is construed as product-focused. [3]

Claims 10 and 11: the meaning of the mark

Claims 10 and 11 narrow the identifying mark to:

Component strength.
Manufacturer identity.

These claims could cover marks corresponding to dosage strength, such as a tactile numerical or symbolic designation, or marks identifying the manufacturer through lettering, logos, or other indicia.

They do not require the mark to be exclusively tactile, visually legible, registered as a trademark, or located on a specific portion of the dosage surface.

Claim 12: blister and dosage-form combination

Claim 12 covers a combination consisting of:

An embossed blister pocket; and
A fast-dissolving dosage form with a corresponding tactile mark.

The claim text refers to a process “as claimed in claim 11,” although claim 11 is itself a method claim focused on manufacturer indicia. That dependency creates a drafting and claim-construction issue. The likely intended scope is a blister pocket and dosage form combination in which the corresponding mark identifies the manufacturer. The unusual dependency could limit enforceability or create litigation risk if a court treats the wording strictly.

Claims 13 through 18: product structure

Claim 13 is the broadest product-oriented claim. It requires:

A fast-dissolving dosage form formed in a blister pocket.
An overall shape defined by the pocket.
A generally continuous dosage surface formed by contact with the blister surface.
A predetermined tactile identifying mark.
A substantially identical embossment on the blister surface.
Three-dimensional discernibility of the mark.

Claims 14 through 18 narrow claim 13 by specifying:

Claim	Limitation
13	Structural relationship between dosage form and embossed blister
14	Freeze-dried in the blister pocket
15	Elevated mark
16	Depressed mark
17	Strength indicia
18	Manufacturer indicia

Claim 13 is potentially more important than claim 1 for product-focused enforcement because it describes the physical relationship between the blister and dosage form. It still requires proof that the dosage surface was formed against a substantially identical blister embossment. A dosage form with a separately applied mark may fall outside the literal claim.

What formulations and dosage forms are protected?

The patent is formulation-neutral. It does not claim a specific active ingredient, excipient, therapeutic class, or pharmacological use.

The likely covered dosage forms include:

Freeze-dried oral dosage forms.
Fast-dissolving tablets.
Porous lyophilized units.
Unit-dose blister products.
Dosage forms formed from a liquid suspension.
Products with raised or recessed tactile indicia.

Claim 2 and claim 14 specifically address freeze-drying. The broader claims do not require freeze-drying and could extend to other forming methods if the dosage form is formed directly in the embossed pocket.

The claims do not expressly require:

A particular disintegration time.
A particular residual moisture level.
A particular dosage-form density.
A specific blister material.
A specific cavity volume.
A particular active pharmaceutical ingredient.

How does thermoforming compare with cold-forming under the patent?

Thermoforming and cold-forming are separate dependent-claim pathways.

Thermoforming generally uses heat to soften a polymer laminate before forming the blister cavity. Claim 5 therefore targets embossed polymeric blister structures made through a heated process.

Cold-forming mechanically shapes a laminate, commonly one containing aluminum foil. Claim 6 covers the process category, while claim 7 separately identifies aluminum laminate.

The patent does not make the blister material limitation universal. A product using plastic laminate may implicate claim 8. A product using aluminum laminate may implicate claim 7. The independent claims remain broader because they do not require either material or forming technique.

How strong is the patent estate for fast-dissolving dosage forms?

The estate represented by U.S. Patent 5,457,895 is narrow in technology but broad in claim architecture.

Strengths

The patent combines process and product coverage. This creates multiple possible infringement theories:

Direct infringement of the in-pocket manufacturing process.
Product infringement based on the transferred tactile mark.
Combination-product infringement involving the blister and dosage form.
Dependent-claim coverage for freeze-drying, blister materials, and mark content.

The claims also avoid limiting the invention to a particular drug. That makes them potentially relevant across multiple orally disintegrating or rapidly dissolving products.

Weaknesses

The patent has several material limitations:

It expired in 2012 under the ordinary pre-URAA patent-term calculation.
The claim language repeatedly requires a correspondence between the blister embossment and dosage-form mark.
“Generally continuous surface” and “substantially identical embossment” may create claim-construction disputes.
The claims do not cover all fast-dissolving dosage forms, only those formed with the specified embossed blister relationship.
Claim 12 has an apparent dependency problem.
Claim 18 appears to refer to “a method as claimed in claim 13,” although claim 13 is a dosage-form claim, creating additional drafting ambiguity.

The patent was stronger as a historical manufacturing barrier than it is as a current exclusivity asset.

When did U.S. Patent 5,457,895 lose exclusivity?

Event	Date or status
U.S. patent grant	October 10, 1995
Ordinary pre-URAA term	17 years from grant
Estimated ordinary expiration	October 10, 2012
Current enforceability	Expired under the ordinary term calculation
Current U.S. generic barrier	None from this patent alone

Patent-term adjustment generally applies to modern applications under the 20-year-from-filing system. This patent was granted from an earlier application and falls within the historical 17-year-from-grant framework. A patent-term extension under 35 U.S.C. § 156 is generally associated with regulatory review of an eligible drug or biological product, not with a packaging and manufacturing patent of this type. [2][4]

What is the Orange Book status of U.S. Patent 5,457,895?

The patent is not drug-specific and does not claim an active ingredient, formulation composition, or method of treating a named disease. On the supplied claim set, it is not the type of patent ordinarily used as an Orange Book drug-substance or drug-product listing.

Orange Book listing is generally associated with patents submitted for an approved drug application and covering the drug substance, drug product, or an approved method of use. A packaging or manufacturing patent may be relevant to a product commercially, but its Orange Book relevance depends on the NDA holder’s submission and FDA acceptance. [5]

Because the patent expired in 2012, it does not present a current Orange Book-based Paragraph IV barrier.

Which companies and products are commercially relevant?

The technology is associated with the broader market for rapidly dissolving and orally disintegrating dosage forms, including products using unit-dose blister packaging. The historical commercial relevance is greatest for manufacturers using:

Lyophilized oral dosage units.
Direct formation in blister cavities.
Child-resistant or unit-dose blister systems.
Tactile or visual product identification.
Proprietary fast-dissolving platforms.

The patent itself does not identify a particular marketed drug or exclusive licensee in the supplied material. No active pharmaceutical ingredient can be mapped to the claims without separate product and prosecution records.

The main commercial companies historically active in this area include platform developers and contract manufacturers associated with orally disintegrating and freeze-dried dosage technologies, including the business historically known as R.P. Scherer and later Catalent-related operations. That commercial association does not establish ownership of this particular patent or a continuing license obligation. Patent ownership, assignment, and licensing must be determined from the recorded chain of title and transaction documents. [1]

What patent litigation and Paragraph IV risks exist?

There is no current Paragraph IV risk from an expired patent. An ANDA applicant does not need to make a Paragraph IV certification against an expired patent because the patent no longer blocks commercial launch.

Historically, a generic applicant could have faced an infringement theory if its product was:

Formed directly inside an embossed blister pocket.
A freeze-dried fast-dissolving dosage unit.
Marked through transfer from a blister embossment.
Sold with the corresponding embossed blister.

A conventional orally disintegrating tablet manufactured separately and later placed into a flat or unembossed blister would present a materially different risk profile. It would generally lack the claimed formation relationship.

No settlement agreement, launch-at-risk arrangement, or active litigation can be established from the claims alone. Since the patent expired more than a decade ago, any historical dispute would now be relevant primarily to damages history, validity analysis, or technology licensing review rather than launch timing.

What generic launch scenarios exist today?

Current launch scenarios are not constrained by U.S. Patent 5,457,895.

Conventional tablet in a blister

Low risk from this patent if the dosage form is manufactured independently and the blister does not transfer an identifying embossment.

Freeze-dried dosage form in an embossed blister

This matches the historical technology most closely. It could have implicated claims 1, 2, 13, and 14 during the patent term. It is no longer blocked by this patent after expiration.

Product with a separately printed or laser-marked identifier

The mark would generally not satisfy the required transfer from an embossed blister surface. Other patents, labeling rules, or trademark rights may still apply, but this patent would not ordinarily control the separate marking process.

Product using an embossed foil or plastic blister

During the patent term, claims 5 through 8 could have increased exposure depending on the forming method and laminate. Today, those dependent claims have no remaining exclusionary effect.

What manufacturing and intellectual-property barriers remain?

The patent’s expiration removes the principal U.S. patent barrier created by this claim set. Remaining barriers may include:

Later-expiring patents covering lyophilized dosage-form composition.
Patents covering porous matrix structures or excipient systems.
Patents covering blister sealing, peelable lids, or child-resistant packaging.
Manufacturing know-how for freeze-drying cycle control.
Equipment and tooling design.
Regulatory validation of unit-dose packaging.
Trademark and trade-dress rights.
Confidential process parameters and quality-control methods.

These rights are separate from U.S. Patent 5,457,895. A freedom-to-operate review for a modern product must distinguish the expired embossed-blister claims from later patents directed to the formulation, manufacturing cycle, packaging line, or approved use.

Key Takeaways

U.S. Patent 5,457,895 covers transferring a tactile identifying embossment from a blister pocket to a fast-dissolving dosage form formed in that pocket.
The principal technology is compatible with freeze-dried dosage forms, thermoformed plastic blisters, and cold-formed or aluminum laminate blisters.
Claims 1 and 13 are the central process and product claims.
Claims 9 and 13 through 18 provide product-oriented coverage but contain product-by-process and correspondence limitations.
Claims 12 and 18 contain drafting irregularities that could have complicated enforcement.
The patent was granted on October 10, 1995, and its ordinary patent term expired on October 10, 2012.
The patent does not claim a drug substance, formulation composition, or therapeutic use.
It does not create a current U.S. Orange Book or Paragraph IV barrier.
Current commercial risk is more likely to arise from later patents covering freeze-dried formulations, blister packaging, manufacturing processes, or regulatory exclusivity.

FAQs

Can a generic manufacturer use a tactile mark on a fast-dissolving tablet today?

Yes, this patent does not prevent such use because it expired in 2012. Later patents, trademarks, or packaging rights may still require separate review.

Does the patent cover every orally disintegrating tablet?

No. It requires a specific relationship between an embossed blister surface and a tactile mark formed on the dosage surface. Tablets made separately from the blister are outside the core concept unless they satisfy all applicable claim limitations.

Does freeze-drying alone create infringement risk under this patent?

No. Freeze-drying is only one limitation in dependent claims 2 and 14. The product or process also must involve formation in an embossed blister pocket and transfer of the corresponding mark.

Could this patent have blocked a product with a printed logo?

Generally, not by itself. The claims focus on a three-dimensional tactile mark produced through an embossed blister surface, not an ordinary printed or digitally applied logo.

Is a license needed for the technology covered by this patent?

No license is required for the expired U.S. patent. A license may still be relevant for separately protected technology, foreign counterpart patents that remain in force, know-how, trademarks, or later-developed manufacturing platforms.

References

United States Patent and Trademark Office. (1995). U.S. Patent No. 5,457,895.
United States Code, 35 U.S.C. §§ 154, 156.
U.S. Court of Appeals for the Federal Circuit. (1997). Atlantic Thermoplastics Co. v. Faytex Corp., 970 F.2d 834.
United States Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, Chapter 2700: Patent Term and Patent Extensions.
U.S. Food and Drug Administration. (2024). Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	197542	⤷ Start Trial
Australia	7801494	⤷ Start Trial
Canada	2149659	⤷ Start Trial
Germany	69426305	⤷ Start Trial
Denmark	0721325	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,457,895

Summary for Patent: 5,457,895